Table 3.
Univariate and multivariate analyses of overall survival in advanced gastric cancer patients receiving immunotherapy and chemotherapy
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (≥ 60vs. < 60 years) | 1.144 (0.808–1.620) | 0.447 | ||
| Sex (male vs. female) | 0.799 (0.535–1.195) | 0.274 | ||
| Drinking history (yes vs. no) | 1.016 (0.700–1.476) | 0.932 | ||
| ECOG PS (0–1 vs. 2) | 0.762 (0.540–1.074) | 0.120 | ||
| Stage (III vs. IV) | 0.739 (0.509–1.075) | 0.113 | ||
| Differentiation (well or moderate vs. poor) | 1.169 (0.815–1.678) | 0.396 | ||
| PD-1+CD8+Tn % (< 21.5 vs. ≥ 21.5) | 1.239(0.878–1.748) | 0.223 | ||
| PD-L1 CPS (< 5 vs. ≥ 5) | 11.86(6.934–20.28) | < 0.001 | 5.224 (2.802–9.740) | < 0.001 |
| PD-1+CD8+T % (< 21.0 vs. ≥ 21.0) | 23.12 (12.63–42.34) | < 0.001 | 16.92 (8.505–33.65) | < 0.001 |
| PD-1+CD8+Tm % (< 64.3 vs. ≥ 64.3) | 28.93 (14.48–57.77) | < 0.001 | 22.82 (10.39–50.14) | < 0.001 |
| PD-1+CD8+T/PD-1+CD4+T ratio(< 0.669 vs. 0.669) | 2.966 (2.071–4.248) | < 0.001 | 2.640(1.734–4.019) | < 0.001 |
PD-1+CD8+T PD-1+CD8+ T cells, PD-1+CD8+Tm memory PD-1+CD8+ T cells, PD-1+CD4+T PD-1+CD4+ T cells, CPS combined positive score, ECOG PS Eastern Cooperative Oncology Group Performance Status